S

Spectrum Pharmaceuticals Inc
F:NTR

Watchlist Manager
Spectrum Pharmaceuticals Inc
F:NTR
Watchlist
Price: 0.925 EUR
Market Cap: 189.9m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of NTR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NTR Relative Value
Base Case
Not Available
S
Worst Case
Base Case
Best Case

Valuation Multiples

8.7
P/S
P/S
Price to Sales
8.7
vs History
vs Industry
Median 3Y
8
Median 5Y
7.2
Industry
7.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.1
Industry
24.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.3
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.3
Industry
22.3
More Details
8.3
P/B
P/B
Price to Book Value
8.3
vs History
vs Industry
Median 3Y
7.6
Median 5Y
5.6
Industry
3.1
More Details
7.6
EV/S
EV/S
Enterprise Value to Sales
7.6
vs History
vs Industry
Median 3Y
6.9
Median 5Y
6.2
Industry
8
More Details
8.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.5
vs History
vs Industry
Median 3Y
7.8
Median 5Y
7
Industry
10.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.5
Industry
5.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.5
Industry
6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2
Median 5Y
-2
Industry
5
More Details
9.5
EV/IC
EV/IC
Enterprise Value to IC
9.5
vs History
vs Industry
Median 3Y
8.6
Median 5Y
8.2
Industry
5.2
More Details

Multiples Across Competitors

NTR Competitors Multiples
Spectrum Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Spectrum Pharmaceuticals Inc
F:NTR
189.9m EUR 8.7 -3.4 -3.1 -3.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 813 875.7 -160 712.3 -195 156 -192 929.1
US
Abbvie Inc
NYSE:ABBV
387.2B USD 6.6 104 16.9 24.6
US
Amgen Inc
NASDAQ:AMGN
150.6B USD 4.3 22.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 5 22.9 10.7 14.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.4 -531.6 -578.9 -563.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.3B USD 8.9 27.9 20.5 21.5
AU
CSL Ltd
ASX:CSL
100.6B AUD 4.3 22.3 14.8 18.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
61.7B USD 25.1 -193.1 -484.4 -332.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD 4.2 13.5 12.1 13.7
NL
argenx SE
XBRU:ARGX
39.9B EUR 15.3 36.5 87.7 91.9
P/E Multiple
Earnings Growth PEG
US
S
Spectrum Pharmaceuticals Inc
F:NTR
Average P/E: 35.7
Negative Multiple: -3.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 712.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
104
88%
1.2
US
Amgen Inc
NASDAQ:AMGN
22.8
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
N/A N/A
AU
CSL Ltd
ASX:CSL
22.3
14%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -193.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
6%
2.3
NL
argenx SE
XBRU:ARGX
36.5
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
S
Spectrum Pharmaceuticals Inc
F:NTR
Average EV/EBITDA: 25.8
Negative Multiple: -3.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 156 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.5
17%
1.2
AU
CSL Ltd
ASX:CSL
14.8
10%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -484.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
9%
1.3
NL
argenx SE
XBRU:ARGX
87.7
727%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
S
Spectrum Pharmaceuticals Inc
F:NTR
Average EV/EBIT: 29
Negative Multiple: -3.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 929.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
19%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.7
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
17%
1.3
AU
CSL Ltd
ASX:CSL
18.4
14%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -332.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
12%
1.1
NL
argenx SE
XBRU:ARGX
91.9
N/A N/A

See Also

Summary
NTR intrinsic value, competitors valuation, and company profile.
DCF Valuation
NTR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NTR stock valuation using valuation multiples.
Wall Street Estimates
NTR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NTR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 281,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.